{
  "chapter": "Heart Failure Drugs",
  "questions": [
    {
      "q_no": 1,
      "question": "Question 1: What is the half-life of digoxin?",
      "options": {
        "a": "24 hrs",
        "b": "40 hrs",
        "c": "72 hrs",
        "d": "60 hrs"
      },
      "correct_answer": "b",
      "explanation": "The plasma half-life of digoxin is around 40 hours (†6-40 hours). Digitoxin \nDigoxin Good (60-‡0%) ˜ral absorption \n‘er„ good (™0-š00 \n%) Plasma protein bindi \nng ™5%(tš/25-7 da„s) \n25%(tš/240 hrs) èlimination \n€epatic metabolis \nm ‰enal excretion (b„ glomerul \nar filtration) Dose adjustment in \nçi‚er failure \nKidne„ failure Therapeutic le‚els of digoxin in the range of 0.5-0.‡ ng/ml are beneficial. An increase in le‚els \n&gt;š.2 ng/mç is associated with increased mortalit„.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Heart Failure Drugs"
    },
    {
      "q_no": 2,
      "question": "Question 2: Digitalis inhibits Na+/ K+ ATPase pump in cardiac muscle cell membrane. €ow does this lead \nto its positi‚e inotropic effect?",
      "options": {
        "a": "ƒ„ decreasing acti‚it„ of Na+/…a++ exchanger causing decreased influx of sodium and ",
        "b": "ƒ„ decreasing efflux of Na+ leading to less negati‚e resting membrane potential and opening of ",
        "c": "ƒ„ increasing intracellular Na+ causing increased efflux of Na+ and increased influx of …a++ ",
        "d": "ƒ„ increasing intracellular Na+ decreasing the acti‚it„ of …a++ pump in the sarcoplasmic "
      },
      "correct_answer": "a",
      "explanation": "The positi‚e ionotropic effect of digitalis is due to decreased acti‚it„ of Na+/…a2+ exchanger \ncausing a decreased influx of sodium and decreased efflux of …a2+. Digitalis selecti‚el„ binds and inhibits the Na+/ K+ATPase pump of m„ocardial fibers \nwhich normall„ pushes Na+ outside and brings K+ inside. When this pump is inhibited, there is \nan intracellular accumulation of Na+ ions. This results in a relati‚e decrease in the expulsion of \n…a2+ ions ‚ia the Na+-…a2+ exchanger (N…›) leading to the accumulation of calcium inside the \ncells resulting in increased contractilit„. 178 \nSold by @itachibot",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Heart Failure Drugs"
    },
    {
      "q_no": 3,
      "question": "Question 3: The action of digoxin will not be affected in which of the following patients?",
      "options": {
        "a": "4†-„ear-old man with chronic li‚er disease",
        "b": "†0-„ear-old woman with electrol„te disturbances",
        "c": "‡2-„ear-old man with renal failure",
        "d": "60-„ear-old woman with m„ocardial infarction"
      },
      "correct_answer": "a",
      "explanation": "The action of digoxin is not affected in chronic li‚er disease. ˜ption ƒ: èlectrol„te disturbances liˆe h„poˆalemia, h„pomagnesemia, and \nh„percalcemia increase digitalis toxicit„. ˜ption …: Digoxin is excreted unchanged primaril„ b„ ˆidne„s b„ glomerular filtration. Therefore, \ndose adjustment of digoxin has to be done in renal failure. ˜ption D: …hances of arrh„thmias increases manifold in post-M‹ duration. €ence, it is generall„ \na‚oided post-M‹ as digitalis itself causes arrh„thmias. Digitoxin \nDigoxin Good ( 60-‡0%) i/‚ also ˜ral absorption \n‘er„ good (™0-š00 \n%) Plasma protein bindi \nng ™5% \n25% èlimination \n€epatic metabolis \nm ‰enal excretion (b„ glomerul \nar filtration) Dose adjustment in \nçi‚er failure \nKidne„ failure",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Heart Failure Drugs"
    },
    {
      "q_no": 4,
      "question": "Question 4: Which of the following does not increase the risˆ of digoxin toxicit„? 171 \nSold by @itachibot",
      "options": {
        "a": "‰enal impairment",
        "b": "€„perˆalemia",
        "c": "€„percalcemia",
        "d": "€„pomagnesemia"
      },
      "correct_answer": "b",
      "explanation": "Digoxin toxicit„ is not increased b„ h„perˆalemia. ‹n h„perˆalemia, the ATPase alpha subunit is dephosphor„lated, which is the binding site of \ndigoxin. This reduces it's binding and effect. Therefore, h„perˆalemia does not increase digoxin \ntoxicit„. Žactors predisposing digoxin toxicit„: • €„poˆalemia (more digoxin binds to the Na+/K+ ATPase) • €„percalcemia (increases the risˆ of arrh„thmia) • €„pomagnesemia (Mg++ is a co-factor for Na+/K+ ATPase) • ‰enal failure (for digoxin)",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Heart Failure Drugs"
    },
    {
      "q_no": 5,
      "question": "Question 5: A patient is to be started on digoxin therap„ for heart failure. Despite alread„ being on \nanother drug, dose adjustment of digoxin is not necessar„ for this patient. ‹dentif„ this drug.",
      "options": {
        "a": "Amiodarone",
        "b": "Œuinidine",
        "c": "…aptopril",
        "d": "çe‚osimendan"
      },
      "correct_answer": "d",
      "explanation": "çe‚osimendan does not increase digitalis toxicit„ and hence would not reœuire dose adjustment of \ndigoxin. ‹t is a combined …a2+ channel sensitizer (troponin … binding) and PDè† inhibitor. 179 \nSold by @itachibot Digoxin is metabolized b„ P-gl„coprotein and drugs that inhibit it increase the plasma le‚els of \ndigoxin and ma„ result in toxicit„. The drugs that increase digoxin toxicit„ are: • Amiodarone • Œuinidine • Propafenone • ‘erapamil • …aptopril • èr„throm„cin • Gentam„cin • ‰anolazine",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Heart Failure Drugs"
    },
    {
      "q_no": 6,
      "question": "Question 6: What is the most appropriate treatment for a patient with se‚ere digoxin toxicit„?",
      "options": {
        "a": "Potassium supplements",
        "b": "Propafenone",
        "c": "Œuinidine",
        "d": "Žab fragments of digoxin antibodies"
      },
      "correct_answer": "d",
      "explanation": "The most appropriate treatment for se‚ere digoxin toxicit„ is purified Žab fragments of digitalis \nantibodies (Digibind). ‹t neutralizes the digoxin action and its dosage is based upon the total dose of digoxin ingested. ˜ption A: K…l infusion is indicated in mild toxicit„ as h„perˆalemia decreases the binding of \ndigoxin b„ dephosphor„lating Na/K ATPase pump. ‹n acute se‚ere poisoning, potassium is not \nindicated as it ma„ alread„ be high in plasma. Potassium is also not indicated when a higher \ndegree of A‘ blocˆ is present. ˜ptions ƒ and …: Œuinidine and propafenone are not indicated in arrh„thmias caused b„ digoxin.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Heart Failure Drugs"
    },
    {
      "q_no": 7,
      "question": "Question 7: An è…G is done for a patient suspected to ha‚e digoxin toxicit„. Which of the following would \n„ou not expect to see on the è…G?",
      "options": {
        "a": "‘entricular bigemin„",
        "b": "Parox„smal atrial tach„cardia with fast ‚entricular rate",
        "c": "‰egularisation of atrial fibrillation",
        "d": "ƒidirectional ‚entricular tach„cardia"
      },
      "correct_answer": "b",
      "explanation": "Digoxin can cause either parox„smal or non-parox„smal atrial tach„cardia with ‚ariable A-‘ blocˆ \nbut not a fast ‚entricular rate. ‰egularisation of atrial fibrillation with complete A-‘ blocˆ and junctional or ‚entricular escape \nrh„thm can occur because of the blocˆade of A-‘ conduction. Due to the blocˆade of A‘ node b„ \ndigoxin, it is contraindicated in WPW s„ndrome. …ommon arrh„thmias associated with digoxin toxicit„: • ‘entricular bigemin„ • Atrio‚entricular junctional rh„thm • ƒidirectional ‚entricular tach„cardia • Premature ‚entricular depolarizations. 180 \nSold by @itachibot",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Heart Failure Drugs"
    },
    {
      "q_no": 8,
      "question": "Question 8: 172 \nSold by @itachibot A patient with heart disease presents to the emergenc„ with se‚ere ‚omiting and blurr„ ‚ision \nand mentions that he sees a greenish-„ellow tinge o‚er all objects. €e then de‚elops \n‚entricular arrh„thmia. What would be the most appropriate drug for immediate \nmanagement?",
      "options": {
        "a": "Procainamide",
        "b": "çignocaine",
        "c": "Atropine",
        "d": "Propranolol"
      },
      "correct_answer": "b",
      "explanation": "The gi‚en clinical scenario is suggesti‚e of digoxin toxicit„. ›anthopsia i.e., „ellowing of ‚ision is \ncharacteristicall„ seen in this condition. çignocaine (and phen„toin) has the least effect on A‘ \nnodal conduction and is the most appropriate drug for the treatment of digoxin-induced \narrh„thmias. ˜ption A: Procainamide and other class ‹A anti-arrh„thmic agents are not indicated in digoxin \ntoxicit„ because of their inhibitor„ effects on A‘ nodal conduction. ˜ption …: Atropine is used for atrial brad„arrh„thmias associated with digoxin toxicit„. ˜ption D: Propranolol is used for atrial tach„arrh„thmias associated with digoxin toxicit„.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Heart Failure Drugs"
    },
    {
      "q_no": 9,
      "question": "Question 9: A patient is diagnosed with congesti‚e heart failure. Which of the following is not prescribed \nto pre‚ent progression and re‚ert cardiac remodelling?",
      "options": {
        "a": "ƒeta blocˆer",
        "b": "A…è inhibitor",
        "c": "Digoxin",
        "d": "Aldosterone antagonist"
      },
      "correct_answer": "c",
      "explanation": "Digoxin has no role in pre‚enting cardiac remodelling. ‹t increases cardiac contractilit„ and \nis indicated for s„mptomatic management of congesti‚e heart failure. Drugs pre‚enting ‚entricular remodelling: • A…è inhibitors/ A‰ƒS • ƒeta-blocˆers • Aldosterone antagonists (spironolactone, eplerenone) The acti‚ation of ‰AAS and the s„mpathetic ner‚ous s„stem leads to the remodelling and \nprogressi‚e ç‘ d„sfunction. The ‰AAS acti‚ation is pre‚ented b„ the A…è inhibitors/A‰ƒs and \nthe aldosterone antagonists (spironolactone), while the o‚eracti‚e s„mpathetic s„stem is inhibited \nb„ the beta-blocˆers.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Heart Failure Drugs"
    },
    {
      "q_no": 10,
      "question": "Question 10: ’ou are starting a treatment regimen containing an angiotensin-con‚erting enz„me inhibitor \nfor a patient with congesti‚e heart failure. Which of the following is true regarding its role in \nthe regimen?",
      "options": {
        "a": "‹t is the drug of choice unless contraindicated",
        "b": "Used as an alternati‚e to diuretics",
        "c": "‹t is a substitute for digitalis",
        "d": "Used as adjuncts onl„ in resistant cases"
      },
      "correct_answer": "a",
      "explanation": "181 \nSold by @itachibot A…è inhibitors and A‰ƒs are the first choice drugs in congesti‚e heart failure (…€Ž) unless \ncontraindicated. ‰enin-angiotensin-aldosterone s„stem (‰AAS) acti‚ation is pi‚otal in the de‚elopment of the \ns„mptoms and disease progression in …€Ž. A…è inhibitors and A‰ƒs afford s„mptomatic as well as disease-modif„ing benefits in …€Ž b„ \ncausing ‚asodilation, retarding/pre‚enting ‚entricular h„pertroph„, m„ocardial cell apoptosis and \nfibrosis.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Heart Failure Drugs"
    },
    {
      "q_no": 11,
      "question": "Question 11: Which of the following drugs can o‚ercome an increase in heart rate and renin release seen in \npatients with …€Ž?",
      "options": {
        "a": "Minoxidil",
        "b": "Metoprolol",
        "c": "Metolazone",
        "d": "Milrinone"
      },
      "correct_answer": "b",
      "explanation": "Metoprolol is a selecti‚e š blocˆer. ƒeta blocˆade reduces the s„mpathetic stimulation of the SA \nnode and thus reduces the heart rate. ‹n the same wa„, š receptors in the ùG apparatus are also \ninhibited b„ metoprolol, and thus, renin release is reduced. ˜ption A: Minoxidil is a K+ channel opener that was earlier used in h„pertensi‚e emergencies for \nits ‚asodilator„ action on blood ‚essels. This has no effect on renin release and heart rate can \nincrease due to reflex s„mpathetic stimulation. ˜ption …: Metolazone is a thiazide diuretic that can be used e‚en in se‚ere renal failure. ˜ption D: Milrinone is an inodilator. ‹t increases cardiac contractilit„ and causes ‚asodilation b„ \ninhibiting the enz„me PDè†.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Heart Failure Drugs"
    },
    {
      "q_no": 12,
      "question": "Question 12: ’ou see the cardiologist prescribe a non-selecti‚e beta-blocˆer for a patient with congesti‚e \nheart failure. €e mentions that the drug has se‚eral beneficial effects. ‹dentif„ the drug.",
      "options": {
        "a": "Propranolol",
        "b": "Pindolol",
        "c": "Metoprolol",
        "d": "…ar‚edilol"
      },
      "correct_answer": "d",
      "explanation": "The drug most liˆel„ being discussed is car‚edilol which is a non-selecti‚e beta-blocˆer appro‚ed \nfor use in mild to se‚ere …€Ž. Additional actions of car‚edilol: • ƒlocˆade of alpha receptors • ƒlocˆade of ç-t„pe calcium channels • Antioxidant effect • Antiproliferati‚e effect ˜ptions A and ƒ: Propranolol and pindolol are non-selecti‚e beta-blocˆers but the„ are not \nappro‚ed for use in …€Ž. ˜ption …: Metoprolol is appro‚ed for use in …€Ž but it is a cardioselecti‚e beta-blocˆer.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Heart Failure Drugs"
    },
    {
      "q_no": 13,
      "question": "Question 13:  blocˆer therap„ is to be started on a patient with congesti‚e heart failure. Which of the \nfollowing statements is false about the therap„?",
      "options": {
        "a": "The drugs should be started at optimum doses",
        "b": "The dose should be graduall„ increased o‚er weeˆs",
        "c": "Special precautions should be taˆen in cases of N’€A class ‹‹‹ and ‹‘",
        "d": "…ar‚edilol and metoprolol are the preferred drugs"
      },
      "correct_answer": "a",
      "explanation": "ƒeta-blocˆers are not started with optimum doses in patients with heart failure. 182 \nSold by @itachibot ƒeta-blocˆer therap„ in …€Ž reœuires caution, proper patient selection, and obser‚ance of se‚eral \nguidelines such as: • Generall„, the starting dose is less than š/‡th (low dose) of the target dose is and then titrated \nupwards slowl„ o‚er weeˆs (doubling e‚er„ 4 weeˆs) • The greatest utilit„ of beta-blocˆer therap„ has been seen in mild to moderate …€Ž (N’€A ‹, ‹‹) • There is no place for beta-blocˆers in decompensated heart disease • …ar‚edilol, bisoprolol, and metoprolol are commonl„ used beta-blocˆers in …€Ž.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Heart Failure Drugs"
    },
    {
      "q_no": 14,
      "question": "Question 14: ’ou are going through the treatment chart of a patient with chronic congesti‚e heart failure. \nWhich of the following drugs will „ou not expect to see?",
      "options": {
        "a": "‹‚abradine",
        "b": "Digoxin",
        "c": "Spironolactone",
        "d": "Adrenaline"
      },
      "correct_answer": "d",
      "explanation": "Adrenaline is used for the treatment of acute decompensated heart failure, not chronic congesti‚e \nheart failure. Drugs used in chronic congesti‚e heart failure include : • Diuretics • A…è inhibitors • Angiotensin receptor blocˆers • Angiotensin receptor-nepril„sin inhibitor - sacubitril-‚alsartan • €„dralazine • Nitrates • Digoxin • Mineralocorticoid receptor antagonists • ‹‚abradine - sinus node inhibitor",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Heart Failure Drugs"
    },
    {
      "q_no": 15,
      "question": "Question 15: A 70-„ear-old man is brought with complaints of se‚ere chest pain. The è…G shows \nanterolateral wall M‹ and echocardiograph„ shows an ejection fraction of †‡%. Which of the 174 \nSold by @itachibot following is the drug of choice for his condition?",
      "options": {
        "a": "Dopamine",
        "b": "Dobutamine",
        "c": "èpinephrine",
        "d": "Norpepinephrine"
      },
      "correct_answer": "b",
      "explanation": "The gi‚en clinical scenario is suggesti‚e of acute congesti‚e heart failure with s„stolic d„sfunction. \nDobutamine is administered as it is the beta-adrenergic agonist of choice for managing this \ncondition. Dobutamine has a well-balanced action with stimulation of cardiac output. ‹t causes less \ntach„cardia than epinephrine and also has an added ad‚antage of a decrease in pulmonar„ arter„ \nwedge pressure. At doses that result in a positi‚e inotropic effect, the beta-š action on the m„ocardium \npredominates. ‹n the ‚asculature, the alpha-š effects are counterbalanced b„ beta-2 effects. The \nnet result is an increase in stroˆe ‚olume, augmented b„ a small decrease in s„stemic ‚ascular \nresistance, thereb„ resulting in a decrease in afterload. 183 \nSold by @itachibot",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Heart Failure Drugs"
    },
    {
      "q_no": 16,
      "question": "Question 16: Which of the following is false about nesiritide?",
      "options": {
        "a": "‹t is a ƒNP analogue",
        "b": "‹t can be used in decompensated …€Ž",
        "c": "‹t can be administered orall„",
        "d": "‹t causes loss of Na+ in the urine"
      },
      "correct_answer": "c",
      "explanation": "Nesiritide is a‚ailable for intra‚enous administration onl„ as it is a peptide and is digested b„ \npeptidases in the G‹T. Nesiritide is a recombinant brain natriuretic peptide (ƒNP). ‹t causes natriuresis and ‚asodilation. \n‹t has a half life of š‡ minutes. ‹t is appro‚ed to relie‚e d„spnoea and other s„mptoms in acute \nrefractor„ decompensated …€Ž.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Heart Failure Drugs"
    },
    {
      "q_no": 17,
      "question": "Question 17: Which enz„me degrades ƒNP?",
      "options": {
        "a": "Neutral endopeptidase",
        "b": "èlastase",
        "c": "Pseudocholinesterase",
        "d": "…arbox„peptidase"
      },
      "correct_answer": "a",
      "explanation": "ƒrain natriuretic peptide (ƒNP) is degraded b„ neutral endopeptidase. Natriuretic peptides: • Atrial natriuretic peptide (ANP) • ƒrain natriuretic peptide • …-t„pe natriuretic peptide Nesiritide is a recombinant ƒNP appro‚ed to relie‚e d„spnoea and other s„mptoms in acute \nrefractor„ decompensated …€Ž.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Heart Failure Drugs"
    },
    {
      "q_no": 18,
      "question": "Question 18: ‹sosorbide dinitrate is indicated for congesti‚e heart failure in combination with which of the \nfollowing ‚asodilators?",
      "options": {
        "a": "Minoxidil",
        "b": "€„dralazine",
        "c": "Nimodipine",
        "d": "Nitrendipine"
      },
      "correct_answer": "b",
      "explanation": "‹sosorbide dinitrate (‹SDN) is indicated in combination with h„dralazine for …€Ž. €„dralazine is a direct ‚asodilator and its mechanism of action is not ˆnown. ‹t also reduces \nnitrate tolerance. The combination of ‹SDN and h„dralazine showed mortalit„ benefits in a specific group of \npopulation (African-Americans).",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Heart Failure Drugs"
    },
    {
      "q_no": 19,
      "question": "Question 19: 175 \nSold by @itachibot A patient with congesti‚e heart failure de‚elops h„ponatremia. Which oral ‚asopressin \nreceptor antagonist will „ou prescribe for him?",
      "options": {
        "a": "Tol‚aptan",
        "b": "…oni‚aptan",
        "c": "ƒoth a and b",
        "d": "Sacubitril"
      },
      "correct_answer": "a",
      "explanation": "Tol‚aptan is an oral ‚asopressin receptor antagonist. ‹t preferentiall„ binds to ‘2 receptors o‚er ‘ša receptors. ‹t has been used in decompensated …€Ž \npatients to restore normal sodium le‚els. …oni‚aptan is also a ‚asopressin receptor antagonist that is administered intra‚enousl„ and binds \nto both ‘2 and ‘ša receptors with similar affinit„. ‹t is more commonl„ used for h„ponatremia \nrather than …€Ž. ˜ral coni‚aptan is not „et a‚ailable.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Heart Failure Drugs"
    },
    {
      "q_no": 20,
      "question": "Question 20: What is the mechanism of action of milrinone?",
      "options": {
        "a": "Stimulation of PDè†",
        "b": "‹nhibition of PDè†",
        "c": "‹nhibition of PDè5",
        "d": "Stimulation of PDè5"
      },
      "correct_answer": "b",
      "explanation": "184 \nSold by @itachibot Milrinone acts b„ inhibition of the enz„me phosphodiesterase-† (PDè †). The PDè-† inhibitors decrease cellular cAMP degradation, resulting in increased le‚els of cAMP. \nThis results in positi‚e ionotropic and chronotropic action of the heart. ‹t also dilates ‚eins and \narteries thereb„ decreasing the preload and afterload.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Heart Failure Drugs"
    },
    {
      "q_no": 21,
      "question": "Question 21: A trial is being conducted to determine the efficac„ of a m„ofilament calcium sensitizer in \npatients with heart failure. Which among the following is the drug liˆel„ being studied?",
      "options": {
        "a": "çe‚osimendan",
        "b": "˜mapatrilat",
        "c": "Sacubitril",
        "d": "ènoximone"
      },
      "correct_answer": "a",
      "explanation": "çe‚osimendan is a m„ofilament calcium senstizer. …alcium sensitizers bind and induce a conformational change in thin-filament regulator„ protein \ntroponin …. Thus increasing the sensiti‚it„ of contractile m„ofilaments to calcium. The result is an \nincreased force of contraction for a gi‚en c„tosolic calcium concentration. ˜ption ƒ: ˜mapatrilat is a dual A…è and nepril„sin inhibitor that failed clinical trials due to \nincreased risˆ of angioedema. ˜ption …: Sacubitril is a nepril„sin inhibitor appro‚ed in combination with ‚alsartan for …€Ž. ˜ption D: ènoximone is a PDè-† inhibitor.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Heart Failure Drugs"
    },
    {
      "q_no": 22,
      "question": "Question 22: Sacubitril is a new drug appro‚ed for chronic heart failure. The mechanism of action of \nsacubitril is:",
      "options": {
        "a": "Angiotensin ‹‹ inhibitor",
        "b": "A…è inhibitor",
        "c": "‰enin inhibitor",
        "d": "Neutral endopeptidase inhibitor"
      },
      "correct_answer": "d",
      "explanation": "Sacubitril is a neutral endopeptidase (nepril„sin) inhibitor. Sacubitril is a prodrug that is acti‚ated to sacubitrilat. ‹t can inhibit the enz„me nepril„sin \n(neutral endopeptidase), which is responsible for the degradation of atrial and brain natriuretic \npeptides (reduction of blood ‚olume). Therefore, it increases the le‚els of atrial and brain \nnatriuretic peptides and lowers blood pressure. ‹n 20š5, the ŽDA appro‚ed the use of sacubitril in combination with ‚alsartan, at a ratio of š:š, for \nthe treatment of chronic heart failure.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Heart Failure Drugs"
    },
    {
      "q_no": 23,
      "question": "Question 23: Which of the following is not used in heart failure?",
      "options": {
        "a": "Thiazide inhibits the metabolism of lithium",
        "b": "Thiazides act as an add on drug to lithium",
        "c": "Thiazides increase the tubular reabsorption of lithium",
        "d": "Thiazides cause water loss therby increase lithium levels"
      },
      "correct_answer": "a",
      "explanation": "Trimetazidine is not used in heart failure. Trimetazidine is a newer antianginal drug that is a pŽ˜› inhibitor which partiall„ inhibits the \nfatt„ acid oxidation pathwa„ in the m„ocardium. This decreases the ox„gen reœuirement of the \nheart. Nesiritide (natriuretic peptide), sacubitril (nepril„sin inhibitor) and metoprolol (beta-blocˆer) are \nused in the treatment of heart failure. 185 \nSold by @itachibot Antihypertensive Drugs",
      "image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/mxpharmacology/Heart_Failure_Drugs_Q23_q.jpg",
      "explanation_image": null,
      "chapter_heading": "Heart Failure Drugs"
    }
  ]
}
